Trial Profile
A phase I, randomized, open-label, active-controlled, three-way treatment trial assessing pharmacokinetics, bioavailability and safety of two single doses of CAM2038 (Buprenorphine FluidCrystal(R) Injection Depot) q4w (once monthly) and four repeat doses of CAM2038 q1w (once weekly) versus active comparators, intravenous and sublingual buprenorphine, in healthy volunteers under naltrexone blockage
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Mar 2020
Price :
$35
*
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid-related disorders
- Focus Pharmacokinetics
- Acronyms CAM
- 09 Jan 2017 Results published in the Advances in Therapy.
- 02 Aug 2014 New trial record
- 29 Jul 2014 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials